Clinical Trial Search

Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants

Primary: Number of Days on Anticoagulation — 24.9 days

Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants

Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants

Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants

Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95

Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016

Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat

Primary: Probability of Maintenance of Sinus Rhythm at One-year Follow up.(Number of Patients Who Maintained Sinus Rhythm) — 61; 34 partecipants — p=< 0.05

Primary: Survival Free of Atrial Fibrillation — 28; 31 participants

Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…

Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV

Primary: Proportion of Days Covered — 1.0; 0.9 Proportion of days covered — p=0.22

Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…

Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001

Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants

Primary: Number of Participants With Acute Success — 53 Participants

Primary: Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Current NOAC Dose According to Sex — 115; 77; 30; 46 Participants

Primary: Incidence of Atrial Fibrillation Requiring Treatment — 9; 21 participants — p=0.02

Primary: Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH) — 1.6; 6.9 percentage of participants — p=0.0009

Primary: Freedom From Procedure-related Serious Adverse Events (SAEs) Within 7-10 Days of the Procedure — 92.7; 88.9 % of participants — p=0.2179

Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048

Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants

Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001

Primary: Interview Process — 34 Participants

Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006

Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76

Primary: Number of Subjects Who Had Atrial Fibrillation Recurrence at 1 Year — 3; 3 participants

Primary: Patient Reported Quality of Life (SF-36) — 29.7; 31.9 score on a scale

Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…